Lipidszintcsökkentó kezelés és rhabdomyolysis.

Translated title of the contribution: Antilipemic therapy and rhabdomyolysis

György Paragh, Zoltán Balogh, László Romics

Research output: Contribution to journalReview article

4 Citations (Scopus)


The authors review the pathomechanism and frequency of side effects (myopathy and rhabdomyolysis) of the lipid lowering agents, statins and fibrates, on the basis of large prospective studies. They review in detail the possible pathomechanism of myopathy as caused by statins and fibrates. The cytochrome P450 enzyme system plays a role in the interaction of other drugs with long term statin therapy. The long term administration of statin and fibrate to patients with primary and secondary hyperlipidemia was considered safe on the basis of our experience and literature data. The combination of statin and fibrate is also considered safe and useful in the treatment of combined hyperlipidemia. As a precautionary measure, we emphasize the ruling out of liver, kidney and muscular diseases in such patients. Lipid lowering therapy is efficient in the primary and secondary prevention of cardiovascular diseases if applied cautiously.

Translated title of the contributionAntilipemic therapy and rhabdomyolysis
Original languageHungarian
Pages (from-to)515-520
Number of pages6
JournalOrvosi hetilap
Issue number11
Publication statusPublished - Mar 16 2003

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antilipemic therapy and rhabdomyolysis'. Together they form a unique fingerprint.

  • Cite this

    Paragh, G., Balogh, Z., & Romics, L. (2003). Lipidszintcsökkentó kezelés és rhabdomyolysis. Orvosi hetilap, 144(11), 515-520.